SPOTLIGHT: BioMarin, Genzyme restructure pact

BioMarin, Genzyme restructure pact
BioMarin and Genzyme have restructured their pact for Aldurazyme, an enzyme replacement treatment for the rare disease MPS 1. The companies say that the revision will reduce management time and provide stronger incentives for each company. Release

Suggested Articles

Galecto picked up $64 million to push its lead lung disease treatment toward an approval in Europe and fund midstage studies for its other programs.

The financing, which attracted support from Roche Venture Fund, sets Palladio up to test its vasopressin V2 receptor antagonist in a kidney disease.

A new atlas of 500,000 cardiac cells could help researchers better understand how a healthy heart operates—and what goes wrong in heart disease.